Sorafenib Tosylate CAS NO.475207-59-1

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Canagliflozin is an SGLT2 inhibitor, which can reduce blood glucose by decomposing glucose and excreting it from the kidney. In addition to good blood glucose control, canagliflozin has the most remarkable effect of reducing fat and few hypoglycemic events, and has broad prospects. In June 9, 2012, according to the results of the 2 phase III clinical trials, Johnson (JNJ) experimental type 2 diabetes canagliflozin was superior to Mercedes Januvia and another old glimepiride in lowering blood sugar. At the same time, canagliflozin has a more significant effect on weight loss; Compared with glimepiride, canagliflozin caused far fewer hypoglycemic events. In January 11, 2013, Johnson's Yang Sen pharmaceuticals company announced its 10 diabetes drug canagliflozin (trade name INVOKANA) Approved by the FDA Expert Committee 1Chemicalbook0:5 vote for the treatment of adult type 2 diabetes. In March 29, 2013, the US Food and Drug Administration (FDA) approved cangreijing (kgglijing) Canagliflozin (trade name Invokana, Johnson's Yang Sen pharmaceutical company) to improve glycemic control in adults with type 2 diabetes. In November 25, 2013, Yang Sen (Janssen) of Johnson (JNJ) announced that the new diabetes INVOKANA (canagliflozin) was approved by the European Commission (EC) for the treatment of adults with type 2 diabetes to improve glycemic control. In September 2014, canagliflozin received positive recommendations from the human pharmaceutical products Committee (CHMP) of the European Drug Administration (EMA). In addition, canagliflozin was approved by FDA in March this year and recently approved by Australia.

Sorafenib tosylate is a new type of multi-target anti-tumor drug, successfully developed by Bayer Pharmaceuticals, Germany, which can simultaneously act on tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it can directly inhibit the proliferation of tumor cells by blocking the cell signaling pathway mediated by RAF/MEK/ERK, and it can also inhibit VEGF and platelet-derived growth factor (PDGF) receptors. Block the formation of tumor blood vessels and indirectly inhibit the growth of tumor cells. It has shown extensive anti-tumor activity in preclinical animal tests. In the Phase III randomized clinical study for the treatment of advanced renal cancer in the United States and Europe, 903 patients with advanced renal cancer who had failed a systemic treatment (biological immune or chemotherapy) were randomly divided into two groups, one group received tosylate Rafenib (Sorafenib for short), another group received placebo treatment Chemicalbook. During the interim analysis, 222 deaths had occurred, and the results showed that the objective effective rates of the two groups were 10% and 2%, respectively, and 74% and 53% of patients had stable tumors. The progression-free survival of the Sorafenib group was twice as long as that of the placebo group (5.8vs2.8 months, hazard ratio was 0.51), and Sorafenib significantly improved the patient's quality of life compared with placebo treatment. The survival time of the Sorafinib group was longer than that of the placebo group, with a hazard ratio of 0.72, but this difference has not yet reached statistical significance. Since this is only the result of the interim analysis, the final comparison of survival can only be made until the final analysis of the trial. Sorafenib treatment is well tolerated, and the main adverse reactions are controllable diarrhea, rash, fatigue, hand-foot syndrome, high blood pressure, hair loss, nausea/vomiting, and loss of appetite.